Phaseline

Targets › TAAR1

TAAR1 (Trace amine-associated receptor 1): drug programs, companies and trials

3 programs from 3 companies in 6 trials: 5 Phase 3, 1 Phase 1; Psychiatry; next expected readout Mar 2027.

Intracellular G protein-coupled receptor for trace amines, which recognizes endogenous amine-containing metabolites such as beta-phenylethylamine (beta-PEA), 3-iodothyronamine (T1AM), isoamylamine (IAA), cadaverine (CAD), cyclohexylamine (CHA), p-tyramine (p-TYR), trimethylamine (TMA), octopamine and tryptamine. Also functions as a receptor for various drugs and psychoactive substances, such as amphetamine and…. (UniProt, Q96RJ0)

Open in Phaseline: the race on TAAR1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Minerva NeurosciencesRoluperidone (MIN-101)
Trace amine-associated receptor 1 (TAAR1) agonist
TAAR1Phase 3Negative Symptoms of SchizophreniaDec 2027
OtsukaUlotaront (SEP-363856)
Serotonin 1a (5-HT1a) receptor agonist; Trace amine-associated receptor 1 agonist
HTR1A, TAAR1Phase 3Schizophrenia; Generalized Anxiety DisorderOct 2028
Newleos TherapeuticsNTX-2001
TAAR1 receptor partial agonist
TAAR1Phase 1Alcohol Use DisorderMar 2027

Conditions

Generalized Anxiety Disorder (3) Schizophrenia (1) Negative Symptoms of Schizophrenia (1) Alcohol Use Disorder (1)

Modalities

small molecule (3)

Companies

Otsuka (1) Minerva Neurosciences (1) Newleos Therapeutics (1)

Related targets

HTR1A (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.